In the obese trial cohort, 1 mg moved 24-hour heart rate by +0.7 bpm in the first week, essentially placebo. In a healthy lean Phase 1b group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population
Rasmussen J, Dun M, Lund AM, et al
buna ramen kan ekeri dengesi bozulmaz
The SOUL trial is being described as a landmark study for cardiovascular outcomes in high-risk diabetes patients
NNMT inhibition increases adipose [S-adenosylmethionine (SAM)] and [Nicotinamide adenine dinucleotide (NAD+)] levels As youll discover later on in this article, theres a good reason why increased production of SAM and NAD+ within fat cells is beneficial